Dr. Enoch Kariuki (CFO, VelosBio)
"I have worked with the Accretio team at both of my last two companies - Synthorx (acquired by Sanofi) and VelosBio (acquired by Merck). At both companies, Accretio’s analyses, insights and clinical strategy recommendations were a critical component of the success in our clinical and BD processes. I would highly recommend them to any biopharma company”
Dr Joe Leveque (CMO, Mirati Therapeutics)
"Accretio develops a differentiated approach based on high-level analytical and scientific expertise. They provide detailed competitive intelligence reports and analysis, as well as forward-thinking and actionable clinical recommendations. I thoroughly endorse Accretio as a trusted and highly collaborative partner to any biotech looking for a team that can help them define and think through their clinical development strategy."
Dr Marcos Milla (Former Head and CSO, Synthorx)
"Accretio is a highly resourceful consultancy firm for analysis of the immunology and oncology competitive environments. Gilles Dufour, its founder, developed deep understanding of these spaces while working at RA Capital; his help in surveying the competitive space has enabled my former team at Synthorx to stay apprised of new developments on therapeutics immunology and immuno oncology indications. Accretio's reports are thorough, reflecting a deep understanding of those fields. I would highly recommend Accretio to any team in search of an impactful, trustworthy consulting firm for competitive intelligence."
Damien Thiéry (Chief Corporate Development, Aquilon Pharma)
"The collaboration with Accretio Management throughout 2020 was undoubtedly an experience that gave us complete satisfaction. Understanding of files, efficiency, speed, flexibility and in-depth work are some of the qualities that define this young and dynamic team. To be recommended to Med/ BioTech Companies without hesitation.